Vitana X : Q2 Report - VITX_Quarter FS_January 31, 2022

VITANA-X INC. AND SUBSIDIARY

CONSOLIDATED INTERIM FINANCIAL STATEMENTS

Six months ended January 31, 2022 and 2021

(Unaudited)

VITANA-X INC. AND SUBSIDIARY

CONSOLIDATED INTERIM FINANCIAL STATEMENTS

Six months ended January 31, 2022 and 2021

(Unaudited)

CONTENTS
Consolidated Interim Balance Sheets	3
Consolidated Interim Statement of Operations	4
Consolidated Interim Statement of Changes in Shareholders' Equity (Deficit)	5
Consolidated Interim Statement of Cash Flows	7
Notes to the Consolidated Interim Financial Statements	8

2

VITANA-X INC. AND SUBSIDIARY

CONSOLIDATED INTERIM BALANCE SHEETS

Six months ended January 31, 2022 and 2021

(Unaudited)

			January 31,		July 31,
in USD	Notes	2022	2021
ASSETS
CURRENT ASSETS
Cash and cash equivalents			3,875		23,035
Receivables due from credit card processor		8,779	40,019
Inventory			443,225		434,250
Other current receivables due from related parties		73,945	74,553
Other current assets			40,226		36,702
TOTAL CURRENT ASSETS		570,050	608,559
NON-CURRENT ASSETS
Fixed assets (net of depreciation)			32,411		40,525
Intangible assets (net of amortization)	4	-	170,799
TOTAL NON-CURRENT ASSETS			32,411		211,324
TOTAL ASSETS			602,461		819,883
LIABILITIES AND STOCKHOLDERS' DEFICIT
CURRENT LIABILITIES
Accounts payable			169,575		342,001
Financial liabilities	5	161,372	191,252
Provisions			218,115		224,563
Other current liabilities		185,169	157,739
TOTAL CURRENT LIABILITIES			734,231		915,555
NON-CURRENT LIABILITIES
Financial liabilities	5	129,487	135,224
Financial liabilities due to directors	5		227,019		-
Financial liabilities - Convertible notes payable	5	91,568	297,473
TOTAL NON-CURRENT LIABILITIES			448,074		432,697
TOTAL LIABILITIES			1,182,305		1,348,252

STOCKHOLDERS' DEFICIENCY

Series A Preferred Stock; $0.0001 par value; 1,000,000 designated; 1,000,000 shares issued (July 31, 2021: NIL)

Series B Preferred Stock; $0.0001 par value; 1,344,756 shares designated; NIL shares issued (July 31, 2021: 1,344,756 )

Common Stock; $0.0001 par value; 5,000,000,000 shares authorized; 3,175,479,712 shares issued (July 31, 2021: 1,366,002,045) Additional paid-in capital

Reserve for unissued shares

Cumulative translation adjustment

Accumulated deficit

6.3	100	-
6.4
		-			134
6.1
317,548	136,600
			4,558,351			2,185,778
	362,391	2,166,314
			111			(5,906)
	(5,818,345)	(5,011,289)

TOTAL STOCKHOLDERS' DEFICIT	(579,844)		(528,369)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	602,461		819,883

See accompanying notes to the consolidated interim financial statements (unaudited).

3

VITANA-X INC. AND SUBSIDIARY

CONSOLIDATED INTERIM STATEMENT OF OPERATIONS

Six months ended January 31, 2022 and 2021

(Unaudited)

			Three months ended		Six months ended
			January 31,		January 31,
	in USD	Notes	2022	2021	2022	2021
	Revenues		147,702		413,330		449,221		413,330
	Cost of goods sold		(133,084)	(163,961)	(343,307)	(163,961)
	Gross profit		14,618		249,369		105,914		249,369
	Operating expenses
	General and administrative		179,077		41,935		478,552		61,144
	Depreciation and amortization	4	56,955	228	173,015	228
	Professional fees		149,349		626,845		380,251		859,995
	Total operating expenses		385,381	669,008	1,031,818	921,367
	LOSS FROM OPERATIONS		(370,763)	(419,639)	(925,904)	(671,998)
	Other income (expenses)
	Fair value changes of derivative financial instruments		-		-		-		255,399
	Gain (loss) from foreign currency transactions		25,847	-	24,352	-
	Other financial expenses		(4,453)		(6,273)		(8,345)		(6,273)
	Total Other Income (Expenses)		21,394	(6,273)	16,007	249,126
	NET LOSS		(349,369)	(425,912)	(909,897)	(422,872)
	NET LOSS PER COMMON SHARE	7
	Basic and diluted		(0.00)		(0.00)		(0.00)		(0.00)
	Weighted average number of shares outstanding		3,019,514,844	1,354,502,045	2,544,515,381	1,354,502,045

See accompanying notes to the consolidated interim financial statements (unaudited).

4

VITANA-X INC. AND SUBSIDIARY

CONSOLIDATED INTERIM STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT)

Six months ended January 31, 2022 and 2021

(Unaudited)

								Additional	Reserve for	Cumulative		Total
		Series A Preferred	Series B Preferred	Common Stock	Paid-in	Unissued	Translation	Accumulated	Shareholders'
in USD	Notes	Number	Amount	Number	Amount	Number	Amount	Capital	Shares	Adjustment	Deficit	Deficit
Balance at July 31, 2021		-	-	1,344,756	134	1,366,002,045	136,600	2,185,778	2,166,314	(5,906)	(5,011,289)	(528,369)
Net loss for the interim period		-	-	-	-	-	-	-	-	-	(560,528)	(560,528)
Foreign currency translation		-	-	-	-	-	-	-	-	804	-	804
Total other comprehensive income		-	-	-	-	-	-	-	-	804	(560,528)	(559,724)

Issuance of Series A Preferred Stock for previous period transactions

Issuance of Common Stock for conversion of notes

Exchange of Series B Preferred Stock for Common Stock

Cash received for the issuance of Common Stock

Common Stock granted for services

Settlement of convertible notes

6.3		1,000,000		100	-	-	-	-	-	(100)	-	-	-
6.1	-	-	-	-	714,722,430	71,472	1,854,986	(1,926,458)	-	-	-
6.1		-		-	(1,344,756)	(134)	887,555,197	88,756	(88,622)	-	-	-	-
6.1	-	-	-	-	-	-	-	298,655	-	-	298,655
6.1		-		-	-	-	-	-	-	-	-	85,500	85,500
5	-	-	-	-	-	-	-	200,905	-	-	200,905

Balance at October 31, 2021		1,000,000	100	-	-	2,968,279,672	296,828	3,952,142	739,316	(5,102)	(5,486,317)	(503,033)
Net loss for the interim period		-	-	-	-	-	-	-	-	-	(349,369)	(349,369)
Foreign currency translation	-	-	-	-	-	-	-	-	5,213	-	5,213
Total other comprehensive income		-	-	-	-	-	-	-	-	5,213	(349,369)	(344,156)

Issuance of Common Stock for conversion of notes

Cash received for the issuance of Common Stock

6.1		-		-	-	-	102,871,041	10,287	294,658	(304,945)	-	-	-
6.1	-	-	-	-	59,038,999	5,904	311,551	(71,980)	-	-	245,475

Common Stock granted for services	6.1		-	-	-	-	45,290,000	4,529	-	-	-	17,341	21,870
Balance at January 31, 2022			1,000,000	100	-	-	3,175,479,712	317,548	4,558,351	362,391	111	(5,818,345)	(579,844)

See accompanying notes to the consolidated interim financial statements (unaudited).

5